Company: RGNT
Filing Date: 2025-09-30
Form Type: F-1/A
Source: 0001213900-25-093302
Chunk: 272

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-09-30
Form: F-1/A
Chunk 272
---
| Valuation allowance                                                            |     |              | (8,956 | ) |     |      | (9,214 | ) |
| Net deferred tax asset                                                         |     | $            |      - |   |     | $    |      - |   |

In assessing the realization of deferred
tax assets, management considers whether it is more likely than not that all or some portion of the deferred tax assets will not be realized.

The ultimate realization of the deferred
tax assets is dependent upon the generation of future taxable income during the periods in which temporary differences are deductible
and net operating losses are utilized. Based on consideration of these factors, the Company recorded a full valuation allowance as of
December 31, 2024 and 2023.

| e. | Income tax expense (benefit): |

The components of profit /(loss) before
tax and a reconciliation of the Company’s theoretical statutory tax benefit to income tax benefit is as follows:

|                                                                           |     | Year Ended   
 December 31, |   2024 |   |     |   |  2023 |   |
|:--------------------------------------------------------------------------|:----|:-------------|-------:|:--|:----|:--|------:|:--|
| Income (loss) before taxes                                                |     | $            | (4,801 | ) |     | $ | 4,132 |   |
| Israeli statutory income tax rate                                         |     |              |     23 | % |     |   |  23.0 | % |
| Theoretical statutory tax benefit (expense)                               |     |              | (1,104 | ) |     |   |   950 |   |
| Revaluation of convertible notes and warrants                             |     |              |    905 |   |     |   |  (464 | ) |
| Temporary deductible difference                                           |     |              |   (164 | ) |     |   |   (26 | ) |
| Profit (losses) for which a valuation allowance                           
 was provided or benefit from loss carryforwards and permanent differences |     |              |    363 |   |     |   |  (460 | ) |
| Income tax expense                                                        |     | $            |      - |   |     | $ |     - |   |

<div align='center'>F-21</div>

REGENTIS BIOMATERIALS LTD.

NOTES TO FINANCIAL STATEMENTS

U.S. dollars in thousands, except share